Key Takeaways & Executive Findings
- •• A novel method integrates a hammerhead ribozyme into structured RNAs via a multibase pair bridge to detect ligand binding, with optimal cleavage achieved at 3-6 base pairs. • The method yields dissociation constants consistent with in-line probing and requires only 1 pmol of RNA, offering high sensitivity. • Application to riboswitch candidate Motif_9307 showed no binding to SAM or other tested ligands, but detected a ligand in yeast extract, demonstrating its utility in complex mixtures. • This approach provides a convenient alternative for measuring ligand-binding events, facilitating the characterization of riboswitch candidates and aptamers.
Abstract
Some structured RNAs, such as riboswitches and aptamers, can bind to their cognate ligands and have been used in biosensors and gene expression control elements. However, current methods for detecting ligand binding to structured RNAs are either severely limited or inconvenient. In this study, we design a multibase pair bridge to integrate a hammerhead ribozyme into structured RNAs to detect ligand binding events. The experimental results demonstrate that the length of the bridge has a significant effect on the cleavage of the ribozyme; optimal cleavage can be achieved with three to six base pairs in the bridge. The dissociation constant (KD) values obtained through this method are in agreement with those determined by in-line probing techniques, and 1 pmol of allosteric ribozyme RNA is sufficient for measurement. We apply this method to evaluate the binding affinity of the riboswitch candidate Motif_9307. Our findings indicate that this motif has no binding affinity for S-adenosylmethionine or several other tested ligands, which is consistent with the results of the in-line probing experiments. Notably, our method reveals an increase in cleavage activity when yeast extract is added as a mixture of ligands, suggesting that the ligand of Motif_9307 is present in the extract. In conclusion, we develop an alternative approach for measuring ligand binding events associated with riboswitch candidates and aptamers.
1. Introduction
Riboswitches are structured non-coding RNAs that are typically located in the 5′ untranslated regions (UTRs) of mRNAs, where they fold and bind to metabolites or other small molecules to regulate gene expression [1,2]. Riboswitches are actually aptamers that carry expression platforms. Aptamers are single-stranded DNA or RNA molecules that can fold into structures and bind to ligands with high specificity and affinity [3–7]. They have been engineered as various sensitive biosensors and nucleic acid drugs [8–14].
The aptamer and expression platform of riboswitches are two overlapping components [2,15]. The aptamer can bind to ligands, and the expression platform can turn on or off gene expression. Examples of expression platforms include ribosomal binding sites (RBSs), rho-independent terminators, and splicing site proximal regions [1,2,16–18]. The conformation of the aptamer changes upon ligand binding, resulting in exposure or sequestration of the expression platform. In addition, tandem riboswitches, such as the guanine aptamer combined with the phosphoribosyl pyrophosphate (PRPP) aptamer, can function as an IMPLY Boolean logic gate to regulate the transcription of messenger RNAs for purine biosynthesis in bacteria [19], indicating their possible applications as logic control circuits [19,20]. Hence, these structured RNAs serve as genetic switches that can activate or repress gene expression in response to changes in the levels of their target ligands [1,17,21].
Loading authentic research manuscript (Pages 1–5)...
Shenglan Zhang, Yinghong Lin, Ting Gao, Binfen Chen, Weibin Wu, Shanshan Fang, Kexin Fan, Yuqing Lai, Yezi Lin, Rongqin Ke, Sanshu Li (2026). Integration of the hammerhead ribozyme into structured RNAs to measure ligand-binding events for riboswitch candidates and aptamers. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025097
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main innovation of this study?
The study introduces a novel method that integrates a hammerhead ribozyme into structured RNAs using a multibase pair bridge, enabling sensitive detection of ligand-binding events for riboswitch candidates and aptamers.
How does the method work?
The method relies on a hammerhead ribozyme whose cleavage activity is modulated by ligand-induced conformational changes in the structured RNA. The bridge length is optimized to 3-6 base pairs for maximal cleavage response.
What are the advantages of this method over existing techniques?
It requires only 1 pmol of RNA, provides KD values consistent with in-line probing, and can detect ligands in complex mixtures such as yeast extract, making it more convenient and sensitive.
What was the outcome for the riboswitch candidate Motif_9307?
The method showed that Motif_9307 does not bind to SAM or several other tested ligands, but it did show increased cleavage activity in the presence of yeast extract, suggesting the presence of its natural ligand in the extract.
What are potential applications of this method?
This method can be used to characterize riboswitch candidates and aptamers, screen for ligands, and develop biosensors and gene expression control elements.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.